Acute lymphoblastic leukaemia in 2017

Immunotherapy for ALL takes the world by storm

In 2017, three groundbreaking immunotherapies for relapsed and/or refractory B-cell acute lymphoblastic leukaemia (ALL) were approved based on impressive outcomes observed in clinical trials. Additional breakthroughs included seminal research into ALL genomics and the importance of adherence to chemotherapy, which will have direct implications for clinical care.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Kantarjian, H. M. et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl. J. Med. 375, 740–753 (2016).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. 2

    Kantarjian, H. M. et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 4, e387–e398 (2017).

    Article  PubMed  Google Scholar 

  3. 3

    Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376, 836–847 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. 4

    von Stackelberg, A. et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J. Clin. Oncol. 34, 4381–4389 (2016).

    CAS  Article  PubMed  Google Scholar 

  5. 5

    Martiinelli, G. et al. Complete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL) following treatment with blinatumomab: results from a phase 2 single-arm, multicenter study (ALCANTARA) [abstract]. Blood 126, 679 (2015).

    Google Scholar 

  6. 6

    Boechner, J. et al. Global registration trial of efficacy and safety of CTL019 in pediatric and young adult patients with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): update to the interim analysis. Haematologica 102, S476 (2017).

    Google Scholar 

  7. 7

    Teachey, D. T. et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor t-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664–679 (2016).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  8. 8

    Qasim, W. et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl Med. 9, eaaj2013 (2017).

    Article  PubMed  Google Scholar 

  9. 9

    Liu, Y. et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat. Genet. 49, 1211–1218 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. 10

    Landier, W. et al. Mercaptopurine ingestion habits, red cell thioguanine nucleotide levels, and relapse risk in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group Study AALL03N1. J. Clin. Oncol. 35, 1730–1736 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Stephen P. Hunger.

Ethics declarations

Competing interests

D.T.T. has served on an advisory board for Amgen and received research funding from Novartis. S.P.H. owns stock in Amgen, Merck, and Pfizer, and has received honoraria from Amgen, Erytech, Jazz Pharmaceuticals, and Spectrum Pharmaceuticals, and consulting fees from Novartis.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Teachey, D., Hunger, S. Immunotherapy for ALL takes the world by storm. Nat Rev Clin Oncol 15, 69–70 (2018). https://doi.org/10.1038/nrclinonc.2017.176

Download citation

Further reading

Search

Quick links

Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing